Big Data Clinical Trials Genetics Genome 
ACRP blog
JUNE 7, 2023
If you hadn’t already noticed, the clinical research enterprise has well and truly entered the era of “big data,” artificial intelligence (AI), and machine learning. Undoubtedly, the expectations for precision medicine are high,” Olsen adds.
Drug Discovery World
JUNE 5, 2024
million to fund a new two-year collaborative partnership with King’s College London (KCL) to validate a portfolio of human genetic driven therapeutic targets for motor neuron disease (MND). Historical pipeline data suggests that drug targets with human genetic disease association are twice as likely to lead to approved drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JULY 11, 2023
Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. One system that has been especially useful in generating relevant and accurate biological data is the patient- derived xenograft (PDX) model for cancer studies.
pharmaphorum
SEPTEMBER 16, 2022
Essentially, the collaboration brought together both “the right expertise and the right technology”, opening up myriad possibilities for targeting GPCRs within the human genome. It also bodes well for improving clinical trial success rates. A notable issue with clinical trials is the homogeneity of the patient database.
Drug Discovery World
FEBRUARY 6, 2024
As AI-designed drugs start to enter large-scale clinical trials, DDW’s Diana Spencer investigates how new digital tools are reinventing and reshaping drug discovery for the future. Automation is also being applied to genomics sample preparation, an area that requires particular robustness and scalability.
Drug Discovery World
FEBRUARY 6, 2023
Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care.
pharmaphorum
SEPTEMBER 18, 2020
Over 85,000 patients in 62 countries were evaluated in clinical trials of Nexium and close to 746 million patient treatments were administered by the end of 2007. TransCelerate BioPharma is the largest initiative of its kind and has end goals of improving the quality of clinical trials and bringing new medicines to patients faster.
Expert insights. Personalized for you.
59 
Let's personalize your content